米国市場銘柄情報

VERV ヴァーヴ・セラピューティクス

銘柄追加

6.160
-0.060-0.96%

終値 04/26 16:00 ET

6.330
+0.170+2.76%

市場後 18:48 ET

5.17億時価総額-1974直近PER

ヴァーヴ・セラピューティクスに関するコメント

ログインコメントを投稿

y f ii

04/02 22:23

$ヴァーヴ・セラピューティクス(VERV.US)$ 6

Trytosaveabit

04/02 19:13

Read the whole PR! But reason for fall

$ヴァーヴ・セラピューティクス(VERV.US)$ However, the sixth participant treated in the 0.45 mg/kg cohort experienced a Grade 3 drug-induced transient increase in serum alanine aminotransferase (ALT) as well as a serious adverse event of Grade 3 drug-induced thrombocytopenia within the first four days after dosing. The participant did not experience any bleeding or other symptoms related to the laboratory abnormalities, and the abnormalities resolved fully within a few ...

Moomoo AI

03/03 21:23

Analysts are optimistic about Verve Therapeutics, predicting reduced losses this year, indicating a move towards profitability. Despite expected slower revenue growth, it's still anticipated to outpace the industry. However, concerns like dilutive stock issuance over the past year persist.

Rainbows and Unicorns: Verve Therapeutics, Inc. (NASDAQ:VERV) Analysts Just Became A Lot More Optimistic

TheMetaHodler

2023/12/30 01:38

$ヴァーヴ・セラピューティクス(VERV.US)$ Loaded on insider buying!

TheMetaHodler

2023/12/14 03:36

$ヴァーヴ・セラピューティクス(VERV.US)$ Google is buying!

Trytosaveabit

2023/12/06 19:56

Insider buy

$ヴァーヴ・セラピューティクス(VERV.US)$ • Krishna Yeshwant, managing partner at Google Ventures and a director at Verve Therapeutics (NASDAQ:VERV), has acquired $18M in Verve common stock.
• In a transaction dated Dec 01, 2023, Yeshwant bought 1.8M shares of Verve's common stock at a price of $10 each.

STD0313

2023/11/16 01:17

$ヴァーヴ・セラピューティクス(VERV.US)$ still 400k shorts available on low volume. Could make another entry. Let the MMs lead on this one. They will decide soon enough

Moomoo AI

2023/11/15 22:31

Verve Therapeutics might need to dilute shares significantly if it needs to cover another year's operations due to the 26% burn rate. The cash burn situation is worth monitoring for shareholders.

Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth

Moomoo AI

2023/11/14 00:26

Verve's results fell short of high expectations, according to analysts. Liver enzyme elevation observed in patients has sparked worries, despite assurances from the company's chief scientific officer.

Verve Therapeutics' Stock Falls 40% as Analysts Question Safety of Cholesterol-cutting Gene-editing Treatment

Tanzh

2023/11/13 05:25

Any expert comments on the data？

$ヴァーヴ・セラピューティクス(VERV.US)$ Looks very promising!

まだコメントはありません

分析

アナリスト評価

データなし

目標株価

データなし

ホット

米国株

総合人気